Aura Biosciences, Inc. (AURA) company profile
Close on Nov 13, 2026Market cap $737.34MP/E –Yield –
About Aura Biosciences
Biological Products, (No Diagnostic Substances), SIC 2836
Aura Biosciences, Inc. is a clinical-stage biotechnology company that develops targeted therapies for solid tumors to eliminate cancer cells while preserving organ function. The company focuses on virus-like drug conjugates, utilizing modified viral capsids linked to light-activated agents that induce acute necrosis and activate an antitumor immune response. Its primary product candidate is belzupacap sarotalocan (bel-sar), which is under development for ocular oncology indications, including early choroidal melanoma, choroidal metastases, and ocular surface cancers, as well as urologic oncology indications like non-muscle invasive bladder cancer. Because its product candidates remain in clinical investigation, the company does not currently sell commercial products; its intended end users are cancer patients and specialized medical practitioners.
Aura Biosciences conducts its research and development operations through clinical trials, including an ongoing global Phase 3 study and early-phase evaluations. The company maintains its principal executive offices and headquarters in Boston, Massachusetts.
Summary of the business section of Aura Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aura Biosciences, Inc.
- Headquarters
- Boston, MA
- Address
- 80 Guest Street 02135
- Phone
- (617) 500-8864
- Website
- aurabiosciences.com
- Employees
- 113, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- AURA
- Exchange
- Nasdaq
- IPO date
- Nov 1, 2021
- Shares outstanding
- 104M, Aug 6, 2026
- Public float
- $321.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1501796
- CUSIP
- 05153U107
- ISIN
- US05153U1079
- FIGI
- BBG00226DGM5
- Share class FIGI
- BBG00226DGP2
- EIN
- 32-0271970
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Natalie C. Holles | See Remarks, Director | 600,118 |
| los Pinos Elisabet de | See Remarks, Director | 703,578 |
| Julie Person | Chief People Officer | 107,611 |
| Susan Abu-Absi | Chief Operating Officer | 134,513 |
| Janet Jill Hopkins | Chief Medical Officer | 380,190 |
| Erica Kratz | Chief Reg. & Quality Officer | 100,885 |
| Amy Elazzouzi | SVP, Finance & PAO | 143,600 |
| Conor Kilroy | See Remarks | 232,693 |
| Anthony S. Gibney | See Remarks | 265,354 |
| Mark Plavsic | Chief Technology Officer | 243,736 |
| Jeremy Bender | Director | 30,000 |
| Sapna Srivastava | Director | 38,500 |
| Teresa Marie Bitetti | Director | 36,000 |
| Antony C. Mattessich | Director | 38,500 |
| David Michael Johnson | Director | 483,839 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Elisabet de los Pinos Former President, Chief Executive Officer and Director | $645.48K | $1.49M | $1.51M | $284.01K | $21.00K | $3.96M | +10% |
| Anthony Gibney Chief Financial and Business Officer | $345.91K | $1.01M | $1.21M | $189.00K | – | $2.75M | – |
| J. Jill Hopkins Chief Medical Officer and President of Research and Development | $551.25K | $926.48K | $469.74K | $220.50K | $21.00K | $2.19M | +79% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 1, 2021
- Offer price
- $14.00
- Securities offered
- 5,400,000
- Gross proceeds
- $75.60M
- Exchange
- Nasdaq
- First trading day
- Oct 29, 2021
- First-day close
- $14.80+5.7%
- Lock-up ends (est.)
- Apr 27, 2022
“Our common stock has been approved for listing on the Nasdaq Global Market under the symbol “AURA.” The initial public offering price of our common stock is $14.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 28, 2026, we had 113 full-time employees and no part-time employees, of which 29 have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 1, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 26, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?